文献速递认知障碍与痴呆

记忆门诊人群中β-淀粉样蛋白、tau蛋白、神经变性分类与抗淀粉样蛋白治疗资格

β-Amyloid, Tau, Neurodegeneration Classification and Eligibility for Anti-amyloid Treatment in a Memory Clinic Population.
PubMed 文献 · Neurology · 2022-09-21

在瑞典卡罗林斯卡大学医院记忆门诊的横断面研究中,纳入2018年4月至2021年2月首次就诊且具备临床和生物标志物数据的410例连续患者,应用ATN分类评估抗淀粉样蛋白治疗潜在资格。多数患者为A-T-N-(54%-57%),A+患病率17%-30%;当AD一致性脑脊液定义为任何A+时,高达13%的患者可能符合治疗资格。

要点

  • 在具备全部基础设施和国家指南的记忆门诊最佳情景下,多数患者不符合抗淀粉样蛋白治疗资格。
  • 无论采用何种生物标志物截断值,多数患者为A-T-N-(54%-57%)。
  • 当要求A+T+时,治疗更多针对痴呆而非MCI阶段(MCI资格高达14%,痴呆高达22%)。

核心结论

  • 在具备必要基础设施和国家痴呆诊断检查指南的记忆门诊环境中,多数患者不符合抗淀粉样蛋白治疗资格。
  • 继续开发具有不同作用机制的疾病修饰治疗是优先事项。

研究设计与样本

  • 横断面研究,纳入瑞典斯德哥尔摩索尔纳卡罗林斯卡大学医院记忆门诊2018年4月至2021年2月首次诊断就诊、签署研究数据库知情同意且具备临床和生物标志物(脑脊液和影像)数据的全部连续患者,共410例。
  • ATN分类基于脑脊液Aβ42(或Aβ42/40;A)、脑脊液磷酸化tau(T)和内侧颞叶萎缩(N);脑脊液标志物应用实验室截断值和数据驱动截断值(通过高斯混合模型确定)进行比较。
  • 抗淀粉样蛋白治疗资格依据已发表的阿杜那单抗推荐评估:AD痴呆或轻度认知障碍(MCI)且无非AD病因证据、认知水平适当、脑脊液谱与AD一致。

主要发现

  • 研究人群410例(52%主观认知障碍,23%MCI,25%任何痴呆;年龄59±7岁,56%女性)。
  • 无论生物标志物截断值如何,多数患者为A-T-N-(54%-57%);A+患病率为17%-30%(数据驱动截断值更高)。
  • 当AD一致性脑脊液定义为任何A+谱时,高达13%的全部患者(MCI患者的27%和痴呆患者的28%)可能符合抗淀粉样蛋白治疗资格。
  • 当要求A+T+谱时,治疗更多针对痴呆而非MCI阶段(MCI资格高达14%,痴呆高达22%);相反,针对早期干预(A+T-N-)时,MCI资格高达12%,痴呆高达2%。

关键数值与推荐

  • ATN分类中A基于脑脊液Aβ42或Aβ42/40,T基于脑脊液磷酸化tau,N基于内侧颞叶萎缩。
  • 脑脊液标志物应用实验室截断值和数据驱动截断值进行比较。
  • 抗淀粉样蛋白治疗资格依据已发表的阿杜那单抗推荐:AD痴呆或MCI且无非AD病因证据、认知水平适当、脑脊液谱与AD一致。

临床怎么用

  • 在具备全部必要基础设施和国家指南的记忆门诊最佳情景下,多数患者不符合抗淀粉样蛋白治疗资格。
  • 当AD一致性脑脊液定义为任何A+谱时,高达13%的全部患者可能符合治疗资格;当要求A+T+谱时,治疗更多针对痴呆而非MCI阶段。
  • 继续开发具有不同作用机制的疾病修饰治疗是优先事项。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: ATN (β-amyloid [Aβ], tau, neurodegeneration) system categorizes individuals based on their core Alzheimer disease (AD) biomarkers. An important potential future use for ATN is therapeutic decision-making in clinical practice once disease-modifying treatments (e.g., anti-amyloid), become widely available. In this cross-sectional study, we applied ATN and estimated potential eligibility for anti-amyloid treatment in a real-life memory clinic with biomarker assessments integrated into the routine diagnostic procedure and all specialized resources available for the implementation of novel treatments. METHODS: We included all consecutive patients at the Karolinska University Hospital Memory clinic in Solna, Stockholm, Sweden, who had their first diagnostic visit in April 2018-February 2021, informed consent for the clinic research database, and available clinical and biomarker (CSF and imaging) data. ATN classification was based on CSF Aβ42 (or Aβ42/40; A), CSF phosphorylated tau (T), and medial temporal lobe atrophy (N). For CSF markers, we applied laboratory cutoffs and data-driven cutoffs for comparison (determined with Gaussian mixture modeling). Eligibility for anti-amyloid treatment was assessed following the published recommendations for aducanumab (AD dementia or mild cognitive impairment [MCI] with no evidence of non-AD etiology, appropriate level of cognition, and AD-consistent CSF profile). RESULTS: The study population consisted of 410 patients (52% subjective cognitive impairment, 23% MCI, and 25% any dementia; age 59 ± 7 years, 56% women). Regardless of biomarker cutoffs, most patients were A-T-N- (54%-57%). A+ prevalence was 17%-30% (higher with data-driven cutoffs). Up to 13% of all patients (27% of those with MCI and 28% of those with dementia) were potentially eligible for anti-amyloid treatment when AD-consistent CSF was defined as any A+ profile. When A+T+ profile was required, treatment was targeted more to the dementia than MCI stage (eligibility up to 14% in MCI and 22% in dementia). The opposite applied to earlier-stage intervention (A+T-N-; eligibility up to 12% in MCI and 2% in dementia). DISCUSSION: In a memory clinic setting with all necessary infrastructure and national guidelines in place for dementia diagnostic examination (best-case scenario), most of the patients did not meet the eligibility criteria for anti-amyloid treatment. Continuing the development of disease-modifying treatments with different mechanisms of action is a priority.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Rosenberg A, Öhlund-Wistbacka U, Hall A, et al. β-Amyloid, Tau, Neurodegeneration Classification and Eligibility for Anti-amyloid Treatment in a Memory Clinic Population. Neurology. 2022. PMID: 36130840. doi:10.1212/WNL.0000000000201043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。